Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Must have Crohn's disease or fistulizing Crohn's disease of at least 3 months duration~* Must have received Remicade, adalimumab or Cimzia at a dose approved for the treatment of Crohn's disease~* Must have failed or been intolerant to Remicade, Humira or Cimzia for treatment of Crohn's disease~* Must be 18 years of age or older~* Must have active Crohn's disease according to the Crohn's Disease Activity Index (CDAI \> =220 and \< =450).~Exclusion Criteria:~* Patients who have had any kind of bowel resection, diversions or placement of a stoma within 6 months~* Are pregnant, nursing or planning pregnancy (both men and women) while enrolled in the study or within 1 year after receiving study agent~* Patients who have received Remicade, Humira or Cimzia \< =8 weeks before the first administration of study drug~* Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug~* Patients with a history of or ongoing chronic or recurrent infectious disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (IP) (Type: PLACEBO_COMPARATOR): None
- Ustekinumab 1mg/kg (IP) (Type: EXPERIMENTAL): None
- Ustekinumab 3 mg/kg (IP) (Type: EXPERIMENTAL): None
- Ustekinumab 6 mg/kg (IP) (Type: EXPERIMENTAL): None
- Placebo IV - Responder - Placebo SC (MP) (Type: PLACEBO_COMPARATOR): None
- Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (Type: PLACEBO_COMPARATOR): None
- Ustekinumab IV - Responder - Placebo SC (MP) (Type: PLACEBO_COMPARATOR): None
- Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) (Type: EXPERIMENTAL): None
- Ustekinumab IV - Nonresponder - Placebo SC (MP) (Type: PLACEBO_COMPARATOR): None
- Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).